Plasma biomarkers of Alzheimer’s neuropathy linked to dementia risk
Aug 01, 2024
Significant associations were seen for all Alzheimer’s disease plasma biomarkers in late life with late-life dementia.
Good Samaritan’s pending deal for second portfolio helps it close on midway point of massive reorganization
By
Kimberly Marselas
Jul 29, 2024
Leaders of the Evangelical Lutheran Good Samaritan Society will be on the ground in Arizona, New Mexico and Texas this week, beginning the transition of another dozen long-term care facilities to new operators...
Temperature extremes tied to higher rates of Missed primary care appointments
Jul 25, 2024
Increased rates of missed appointments were seen for temperatures 89 degrees F.
Telehealth only partially offset decreased primary care visits during pandemic
Jul 23, 2024
The magnitude of those changes varied significantly by patient demographic characteristics.
Commercial insurance market in ‘state of flux’ for senior housing and care
By
Kathleen Steele Gaivin
Jul 22, 2024
The commercial insurance market for long-term care operators “is in a state of flux, influenced by both lingering effects of the pandemic and broader economic factors,” Janice Loper, vice president...
Meet Mary Cate Spires, 2024 Rising Star honoree
By
Foster Stubbs
Jul 15, 2024
Mary Cate Spires, vice president of marketing and digital strategy at The Arbor Company in Atlanta is a Rising Star honoree in the 2024 McKnight’s Women of Distinction awards program.
Nightmares in midlife may point to future cognitive decline, dementia
Jul 12, 2024
The findings were seen in middle-aged and older adults from the general population who did not have Parkinson’s disease.
Meet Lesly Martinez, 2024 Rising Star honoree
By
Foster Stubbs
Jul 11, 2024
Lesly Martinez, regional vice president at Atria Senior Living in Louisville, KY, is a Rising Star honoree in the 2024 McKnight’s Women of Distinction awards program.
Self-administered gerocognitive exam improves detection of cognitive issues in primary care
Jul 02, 2024
Detection rates appear to increase during nonacute office visits.
Mean cost of bringing new drug to US market Is $879.3 million
Jul 02, 2024
R&D has remained relatively stable among large pharma companies despite a 27.3% growth in sales.